Phase 2 DMT Stroke Study Design Finalized Following encouraging results from AGN.c AGNPF’s Phase 1 study of DMT for stroke treatment, AGN is now advancing and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.
Worth noting that AGN is the world’s 1st company to investigate DMT for the treatment of stroke and its ability to promote neuroplasticity in the healing of brain injuries.
With ethics submission planned for later in Q3 and the study starting a short time after approval, I’m keeping an eye on AGN at their current price as the global stroke treatment market is expected to reach a value of $15B by the Year 2027 and AGN is at the forefront of innovative treatments.
https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/189/algernon-neuroscience-announces-40-patient-phase-2